GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » 3-Year RORE %

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) 3-Year RORE % : 20.78% (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % for the quarter that ended in Sep. 2024 was 20.78%.

The industry rank for Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % or its related term are showing as below:

SHSE:600521's 3-Year RORE % is ranked better than
71.11% of 976 companies
in the Drug Manufacturers industry
Industry Median: -0.625 vs SHSE:600521: 20.78

Zhejiang Huahai Pharmaceutical Co 3-Year RORE % Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co 3-Year RORE % Chart

Zhejiang Huahai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.96 70.14 -8.02 12.42 20.69

Zhejiang Huahai Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.22 20.69 32.20 20.78 -

Competitive Comparison of Zhejiang Huahai Pharmaceutical Co's 3-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Huahai Pharmaceutical Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % falls into.



Zhejiang Huahai Pharmaceutical Co 3-Year RORE % Calculation

Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.78-0.48 )/( 2.01-0.54 )
=0.3/1.47
=20.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Zhejiang Huahai Pharmaceutical Co  (SHSE:600521) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Zhejiang Huahai Pharmaceutical Co 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Huahai Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Xunqiao, Zhejiang Province, Linhai, Linhai, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in Research & Development, production and sales of multi-dosage preparations, biological drugs, innovative drugs and specialty APIs.
Executives
Lin Li Hong senior management
Xu Mi senior management
Gang Hui senior management
He Bin senior management
Kong Xiao Fang senior management
Chen Bao Hua Director
Shang Fei senior management
Du Jun Director
Su Yan Director
Chen Dun Yuan senior management
Li Hong Director
Guo Si Jia senior management
Li Min senior management
Xu Bo senior management
Chen Qi Mao senior management

Zhejiang Huahai Pharmaceutical Co Headlines

No Headlines